Published on June 30, 2016   59 min
Please wait while the transcript is being prepared...
Good day and welcome. I'm Jerry Sebag, Professor of Clinical Ophthalmology at the Doheny Eye Institute, and Founding Director of the VMR Institute for Vitreous Macula and Retina in Southern California. The topic of my lecture is vitreous, which has been a subject of great interest to me for almost four decades. A great deal has been learned about vitreous during this time and it's my pleasure share some of the most recent information with you and hopefully stimulate your interest.
There has been a growth of knowledge in vitreous as I alluded to, beginning back in 1930 when Sir Stewart Duke-Elder published a monograph on vitreous that was primarily scientific, had very little clinical information. The monograph was 72 pages long. The next major publication on vitreous was in 1989, also a monograph, and that book was 173 pages, containing a lot of scientific information, but many clinical insights. By 2002, it was no longer possible for a single author to write on the subject of vitreous, and thus the subject of the rapport de la Societe Francaise d'Ophtalmologie was Pathologie du vitre and this multi-authored text was 493 pages long, indicating the expansion of knowledge both in scientific and clinical domains. Last year, the most recent contribution to this field was a 956-page treatise that was co-authored by 90 individuals from all over the world, covering subjects from a very scientific perspective to many clinical applications of the basic science knowledge that's been garnered over the past several decades. This tremendous increase in knowledge in vitreous has enabled a greater appreciation of the role of vitreous in blinding disorders . And I hope today's lecture will give you some insight into this knowledge, and also an eye to the future at where we are headed.